Accumulating evidence from in vitro and in vivo models together with clinical studies collectively suggests that EZH2 is upregulated in various malignant solid tumors such as lung, hepatocellular, ovarian, colorectal and breast cancers. Here, EZH2 is linked to breast carcinoma.